EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis

Karan Sachdeva iD, Dhruv Manik, Tarun Chhibba, Ashwin Ananthakrishnan iD

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izag075 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Karan Sachdeva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Skin Diseases, Eye Diseases, Musculoskeletal Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Leona M. and Harry B. Helmsley Charitable Trust and the National Institutes of Health, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Extraintestinal manifestations (EIMs) occur in one-fifth of patients with inflammatory bowel diseases (IBDs) (Crohn’s disease[CD]; ulcerative colitis [UC]). As advanced therapies (ATs) for IBD become more targeted, effectiveness for luminal disease may not be extrapolatable to EIMs. We conducted a systematic review to evaluate the efficacy of ATs on EIMs in IBD.

Methods

We conducted searches in PubMed/Embase (inception March 2025) for studies of any of the 5 FDA approved AT classes (tumor necrosis factor [TNF] antagonists, Janus kinase [JAK] inhibitors, anti-integrins, anti-interleukins [anti-ILs], and S1P receptor modulators) for musculoskeletal (arthritis, arthralgias), dermatologic (erythema nodosum, pyoderma gangrenosum), or ocular EIMs in patients with IBD. The primary outcome was clinical improvement. The pooled improvement rates by EIM type and AT class were calculated using a random effects model to account for anticipated heterogeneity.

Results

A total of 49 studies were included in the final analysis (6 randomized clinical trials [RCTs], 1 pooled analysis of clinical trials, and 42 observational studies). For musculoskeletal EIMs, TNF antagonists achieved response in 61% of patients, with higher response rates for peripheral (73%) than axial (57%) arthritis. JAK inhibitors were similarly effective (65%) while vedolizumab had significantly lower efficacy (42% improvement), particularly for axial arthritis (12%). For dermatologic EIMs, systemically directed ATs had high efficacy (TNF antagonists 89%, anti-IL 91%). There was a paucity of data on ocular EIMs.

Conclusion

Systemically directed ATs (TNF-antagonists, JAK inhibitors, anti-ILs) demonstrated strong efficacy for musculoskeletal or cutaneous EIMs; vedolizumab achieved clinical response in lower rates, particularly for axial arthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesSkin DiseasesEye DiseasesMusculoskeletal DiseasesHumansArthritis

Stichwörter der Autor:innen

advanced therapiesdermatologicextraintestinal manifestationsmusculoskeletalocularresponse

Autor:innen und Institutionen

  • Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, United States.
  • Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
  • Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

ORCID-Profile: Karan Sachdeva, Ashwin Ananthakrishnan

Förderung

  • The Leona M. and Harry B. Helmsley Charitable Trust and the National Institutes of Health
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sachdeva, K., Manik, D., Chhibba, T., & Ananthakrishnan, A. (2026). Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag075

Vancouver

Sachdeva K, Manik D, Chhibba T, Ananthakrishnan A. Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag075

BibTeX
@article{Sachdeva2026,
  author = {Sachdeva, Karan and Manik, Dhruv and Chhibba, Tarun and Ananthakrishnan, Ashwin},
  title = {Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag075}
}
Kostenlos starten →